Stock Fundamentals

Company Information

▼
Company Name
Amgen Inc
Sector
Healthcare
Industry
Drug Manufacturers - General
Exchange
NASDAQ
ISIN: US0311621009
CIK: 0000318154
CUSIP: 031162100
Currency: USD
Full Time Employees: 31,500
Phone: 805 447 1000
Website: https://www.amgen.com
Fiscal Year End: December
IPO Date: Jun 17, 1983
Description:

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including PROLIA, REPATHA, OTEZLA, ENBREL, EVENITY, XGEVA, TEPEZZA, BLINCYTO, NPLATE, TEZSPIRE, KYPROLIS, ARANESP, KRYSTEXXA AND VECTIBIX, MVASI, PAVBLU, UPLIZNA, IMDELLTRA/IMDYLLTRA, AMJEVITA/AMGEVITA, TAVNEOS, NEULASTA, LUMAKRAS/LUMYKRAS, RAVICTI, PARSABIV, AIMOVIG, WEZLANA/WEZENLA, AND PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; BEONE MEDICINES LTD. to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. The company was incorporated in 1980 and is he

Address:

One Amgen Center Drive, Thousand Oaks, CA, United States, 91320-1799

Directors & Officers

▼
Name Title Year Born
Mr. Robert A. Bradway Chairman & CEO 1963
Mr. Peter H. Griffith Executive VP & CFO 1959
Dr. David M. Reese M.D. Executive VP & CTO 1963
Mr. Murdo Gordon Executive Vice President of Global Commercial Operations 1967
Dr. James E. Bradner M.D. Executive Vice President of Research & Development 1972
Mr. Esteban Santos Executive Vice President of Operations 1968
Mr. Matthew C. Busch Chief Accounting Officer & VP of Finance 1975
Mr. Scott Skellenger Senior VP & Chief Information Officer NA
Mr. Howard Y. Chang M.D., Ph.D. Senior VP of Global Research & Chief Scientific Officer NA
Casey Capparelli Executive Director of Investor Relations NA

Institutional Holders

▼
Holder Name Shares Date Reported % Out Value % Change
Vanguard Group Inc 54.84M Dec 31, 2025 10.17% $0.26 1.79%
BlackRock Inc 46.03M Sep 30, 2025 8.54% $0.23 -1.21%
State Street Corp 29.30M Sep 30, 2025 5.44% $0.29 -0.18%
Capital Research & Mgmt Co - Division 3 19.19M Sep 30, 2025 3.56% $0.87 1.49%
Capital World Investors 18.80M Sep 30, 2025 3.49% $0.72 11.48%
Morgan Stanley - Brokerage Accounts 15.91M Sep 30, 2025 2.95% $0.27 -1.69%
Geode Capital Management, LLC 13.27M Sep 30, 2025 2.46% $0.24 1.91%
Charles Schwab Investment Management Inc 11.81M Dec 31, 2025 2.19% $0.60 -12.84%
PRIMECAP Management Company 8.90M Dec 31, 2025 1.65% $2.21 -8.27%
JPMorgan Chase & Co 8.46M Sep 30, 2025 1.57% $0.07 118.76%
Wells Fargo & Co 7.16M Sep 30, 2025 1.33% $0.38 -2.10%
NORGES BANK 6.61M Dec 31, 2025 1.23% $0.23 10.96%
Northern Trust Corp 6.14M Sep 30, 2025 1.14% $0.22 0.04%
Bank of America Corp 5.19M Sep 30, 2025 0.96% $0.10 -6.92%
Capital Research Global Investors 4.73M Sep 30, 2025 0.88% $0.25 2.66%
UBS Asset Mgmt Americas Inc 4.55M Sep 30, 2025 0.84% $0.28 -13.88%
Royal Bank of Canada 4.53M Sep 30, 2025 0.84% $0.21 -50.07%
Amvescap Plc. 4.47M Sep 30, 2025 0.83% $0.20 6.61%
The Goldman Sachs Group Inc 4.45M Sep 30, 2025 0.82% $0.15 5.09%
UBS Group AG 4.23M Sep 30, 2025 0.79% $0.19 -7.53%

Shares Statistics

▼
Shares Outstanding: 539.07M
Shares Float: 537.73M
% Insiders: 49.90%
% Institutions: 8,504.10%
Short % Float: 2.69%

🏆 Top 10 Institutional Holders

▼
Rank Holder Name Shares Held % of Shares Change Date Reported
1 Vanguard Group Inc 54.84M 10.17% ▲ 1.79% Dec 31, 2025
2 BlackRock Inc 46.03M 8.54% ▼ 1.21% Sep 30, 2025
3 State Street Corp 29.30M 5.44% ▼ 0.18% Sep 30, 2025
4 Capital Research & Mgmt Co - Division 3 19.19M 3.56% ▲ 1.49% Sep 30, 2025
5 Capital World Investors 18.80M 3.49% ▲ 11.48% Sep 30, 2025
6 Morgan Stanley - Brokerage Accounts 15.91M 2.95% ▼ 1.69% Sep 30, 2025
7 Geode Capital Management, LLC 13.27M 2.46% ▲ 1.91% Sep 30, 2025
8 Charles Schwab Investment Management Inc 11.81M 2.19% ▼ 12.84% Dec 31, 2025
9 PRIMECAP Management Company 8.90M 1.65% ▼ 8.27% Dec 31, 2025
10 JPMorgan Chase & Co 8.46M 1.57% ▲ 118.76% Sep 30, 2025

Valuation Metrics

▼
Enterprise Value: $254.72B
Trailing P/E: 27.23
Forward P/E: 17.67

Financial Highlights

▼
Market Cap: $209.14B
EBITDA: $16.62B
P/E Ratio: $27.23
PEG Ratio: $2.60
Book Value: $16.07
Dividend/Share: $9.52
Dividend Yield: 2.51%
Earnings/Share: $14.25
Profit Margin: 20.98%
Operating Margin: 30.55%
ROA (TTM): 7.93%
ROE (TTM): 106.10%
Revenue (TTM): $36.75B
Revenue/Share (TTM): $68.31
Earnings Growth (YOY): 112.10%
Revenue Growth (YOY): 8.60%

Stock Price History

▼

1 Year Price History

2 Years Price History

5 Years Price History

10 Years Price History

Download Financials (Excel)

Financial Charts

▼

Revenue & Net Income (Yearly)

Revenue & Net Income (Quarterly)

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Yearly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Earnings Per Share (EPS) History

▼

Financial Ratios (Yearly)

▼

Financial Ratios (Quarterly)

▼

Earnings History

▼

Balance Sheet (Yearly)

▼

Financial Ratios

▼
Date Current Ratio Debt/Equity Debt/Assets Interest Coverage Debt/EBITDA
2025-12-31 1.14x 6.31x 0.90x 3.88x 3.45x
2024-12-31 1.26x 10.23x 0.94x 2.30x 4.50x
2023-12-31 1.65x 10.37x 0.94x 2.75x 8.18x
2022-12-31 1.41x 10.64x 0.94x 6.80x 3.20x
2021-12-31 1.59x 4.97x 0.89x 6.38x 2.95x
2020-12-31 1.81x 3.51x 0.85x 7.24x 2.54x
2019-12-31 1.44x 3.09x 0.84x 7.51x 2.37x
2018-12-31 2.79x 2.71x 0.81x 7.37x 2.63x
2017-12-31 5.49x 1.40x 0.68x 7.65x 2.75x
2016-12-31 4.11x 1.16x 0.62x 7.77x 2.76x
2015-12-31 4.45x 1.12x 0.61x 7.74x 2.82x
2014-12-31 4.95x 1.19x 0.63x 5.78x 3.51x
2013-12-31 3.44x 1.45x 0.67x 5.74x 4.24x
2012-12-31 3.81x 1.39x 0.65x 5.30x 3.71x
2011-12-31 4.80x 1.13x 0.61x 7.07x 3.68x
2010-12-31 3.52x 0.56x 0.45x 9.18x 1.93x
2009-12-31 4.89x 0.47x 0.43x 9.53x 1.55x
2008-12-31 3.12x 0.50x 0.44x 9.46x 1.53x
2007-12-31 2.11x 0.63x 0.48x 1.86x 1.87x
2006-12-31 1.67x 0.48x 0.44x 1.68x 1.49x
2005-12-31 2.57x 0.19x 0.30x 167.17x 0.70x
2004-12-31 2.21x 0.26x 0.33x 3.16x 1.10x
2003-12-31 3.01x 0.16x 0.26x 30.42x 0.82x
2002-12-31 4.19x 0.17x 0.25x -0.06x 1.19x
2001-12-31 3.85x 0.06x 0.19x 7.58x 0.18x
2000-12-31 3.41x 0.07x 0.20x 2.84x 0.20x
1999-12-31 2.49x 0.03x 0.26x 3.24x 0.07x
1998-12-31 2.10x 0.04x 0.30x 5.04x 0.08x
1997-12-31 2.08x 0.01x 0.31x 6.94x 0.03x
1996-12-31 2.34x 0.06x 0.31x 9.27x 0.12x
1995-12-31 2.49x 0.04x 0.31x 9.22x 0.08x
1994-12-31 2.08x 0.08x 0.36x 3.35x 0.13x
1993-12-31 2.56x 0.09x 0.34x 5.66x 0.18x
1992-12-31 2.81x 0.00x 0.32x 3.83x 0.00x
1991-12-31 2.00x 0.00x 0.39x 1.75x 0.01x
1990-12-31 3.17x 0.00x 0.23x N/A 0.02x
1989-12-31 3.30x 0.01x 0.39x 7.46x 0.03x
1988-12-31 6.48x 0.01x 0.22x -1.02x 0.66x
1987-12-31 9.30x 0.01x 0.15x -0.36x -1.33x
1986-12-31 11.22x 0.01x 0.13x -0.23x 0.42x
1985-12-31 14.85x 0.01x 0.14x -0.60x 0.31x

Insider Trading

Date Insider Name Title Transaction Type Shares Price Value
Jan 29, 2026 David Taylor N/A Sale N/A $342.94 N/A
Jan 23, 2026 Ro Khanna N/A Sale N/A $344.75 N/A
Jan 16, 2026 David Taylor N/A Purchase N/A $330.41 N/A
Dec 03, 2025 David Taylor N/A Sale N/A $345.42 N/A
Nov 20, 2025 Nancy A Grygiel N/A Sale 3.14K $337.26 $1.06M
Nov 12, 2025 Murdo Gordon N/A Sale 6.88K $336.83 $2.32M
Nov 12, 2025 Rachna Khosla N/A Sale 890.00 $336.24 $299.25K
Oct 24, 2025 Marjorie Taylor Greene N/A Purchase N/A $291.76 N/A
Sep 29, 2025 Ro Khanna N/A Sale N/A $273.97 N/A
Sep 25, 2025 Lisa C. McClain N/A Sale N/A $271.18 N/A
Sep 11, 2025 Marjorie Taylor Greene N/A Purchase N/A $282.73 N/A
Sep 04, 2025 Sheldon Whitehouse N/A Sale N/A $280.10 N/A
Aug 20, 2025 Nancy A Grygiel N/A Sale 1.27K $296.99 $376.29K
Jun 24, 2025 Lisa C. McClain N/A Purchase N/A $277.49 N/A
Jun 06, 2025 Cliff Bentz N/A Purchase N/A $290.33 N/A
Jun 05, 2025 Rachna Khosla N/A Sale 1.50K $289.68 $434.52K

📦 Raw API Data (JSON Explorer)

▼

Watchlist

0

No stocks in watchlist

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about AMGN.US!